Centiva Capital LP Sells 23,824 Shares of The Cooper Companies, Inc. (NASDAQ:COO)

Centiva Capital LP lessened its stake in The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 83.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,795 shares of the medical device company's stock after selling 23,824 shares during the quarter. Centiva Capital LP's holdings in Cooper Companies were worth $529,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in COO. Kayne Anderson Rudnick Investment Management LLC boosted its position in Cooper Companies by 3.0% during the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 7,820,590 shares of the medical device company's stock worth $682,738,000 after purchasing an additional 231,155 shares during the period. Victory Capital Management Inc. raised its holdings in Cooper Companies by 23.0% in the 3rd quarter. Victory Capital Management Inc. now owns 3,950,119 shares of the medical device company's stock valued at $435,856,000 after acquiring an additional 737,726 shares during the period. Impax Asset Management Group plc lifted its position in Cooper Companies by 31.0% during the second quarter. Impax Asset Management Group plc now owns 2,359,798 shares of the medical device company's stock worth $205,511,000 after acquiring an additional 558,886 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Cooper Companies by 11.9% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,818,610 shares of the medical device company's stock valued at $200,665,000 after purchasing an additional 194,118 shares during the last quarter. Finally, Champlain Investment Partners LLC increased its stake in shares of Cooper Companies by 8.0% during the third quarter. Champlain Investment Partners LLC now owns 1,818,345 shares of the medical device company's stock worth $200,636,000 after purchasing an additional 134,875 shares during the period. 24.39% of the stock is owned by institutional investors.

Cooper Companies Trading Down 4.4 %

COO traded down $4.53 during midday trading on Friday, hitting $98.70. 3,694,024 shares of the company were exchanged, compared to its average volume of 1,287,907. The firm has a market capitalization of $19.66 billion, a P/E ratio of 50.62, a P/E/G ratio of 2.28 and a beta of 0.97. The firm's 50 day moving average price is $104.49 and its 200-day moving average price is $98.80. The company has a quick ratio of 1.18, a current ratio of 1.99 and a debt-to-equity ratio of 0.33. The Cooper Companies, Inc. has a 1-year low of $82.69 and a 1-year high of $112.38.

Cooper Companies (NASDAQ:COO - Get Free Report) last released its quarterly earnings results on Thursday, December 5th. The medical device company reported $1.04 EPS for the quarter, topping the consensus estimate of $1.00 by $0.04. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.03 billion. Cooper Companies had a return on equity of 9.08% and a net margin of 9.45%. The firm's revenue was up 9.8% on a year-over-year basis. During the same quarter last year, the business posted $0.87 earnings per share. As a group, equities analysts forecast that The Cooper Companies, Inc. will post 4.03 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on COO. Robert W. Baird raised their price target on shares of Cooper Companies from $118.00 to $125.00 and gave the stock an "outperform" rating in a research report on Thursday, August 29th. Needham & Company LLC reissued a "hold" rating on shares of Cooper Companies in a research report on Friday. Stifel Nicolaus reaffirmed a "buy" rating and issued a $115.00 price objective (up from $110.00) on shares of Cooper Companies in a report on Thursday, August 29th. StockNews.com upgraded Cooper Companies from a "hold" rating to a "buy" rating in a research report on Tuesday, December 3rd. Finally, Wells Fargo & Company raised their price target on Cooper Companies from $115.00 to $118.00 and gave the stock an "overweight" rating in a research report on Friday. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Cooper Companies presently has a consensus rating of "Moderate Buy" and an average price target of $117.00.

Insider Buying and Selling

In other news, CEO Albert G. White III sold 114,992 shares of the company's stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $110.53, for a total value of $12,710,065.76. Following the transaction, the chief executive officer now directly owns 165,273 shares in the company, valued at approximately $18,267,624.69. This represents a 41.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Agostino Ricupati sold 1,601 shares of the business's stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $108.03, for a total transaction of $172,956.03. Following the completion of the sale, the chief accounting officer now directly owns 4,818 shares of the company's stock, valued at approximately $520,488.54. This trade represents a 24.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.00% of the stock is currently owned by corporate insiders.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.